Literature DB >> 2992558

Differential effect of platelet inhibitors in normal and in hypercholesterolaemic subjects.

M Aviram, G Winterstein, J G Brook.   

Abstract

Dibutyryl cyclic AMP, forskolin, dipyridamole and butyl imidazole inhibited platelet aggregation (induced by ADP or collagen) in washed platelets more than in platelet-rich plasma preparations. Aspirin, indomethacin and epoprostenol (prostacyclin, PGI2) showed no preferential inhibition of these platelet preparations. When platelet-rich plasma from either normal or familial hypercholesterolaemic (FH) subjects was used, aspirin, indomethacin and dipyridamole (but not forskolin) inhibited platelet aggregation in normal subjects more than in FH patients. When low doses of aspirin (75 mg daily for 7 days) or dipyridamole (250 mg, single dose) were administered in vivo, platelet aggregation was inhibited more in the normal subjects in comparison to the patient group.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2992558      PMCID: PMC1463878          DOI: 10.1111/j.1365-2125.1985.tb02705.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  Platelet thromboxanes and serum-cholesterol.

Authors:  E Tremoli; G Folco; E Agradi; C Galli
Journal:  Lancet       Date:  1979-01       Impact factor: 79.321

2.  Platelet function and lipoprotein levels after plasma-exchange in patients with familial hypercholesterolaemia.

Authors:  G Brook; G Winterstein; M Aviram
Journal:  Clin Sci (Lond)       Date:  1983-06       Impact factor: 6.124

Review 3.  Evaluation of platelet-inhibiting drugs in models of atherosclerosis.

Authors:  R N Saunders
Journal:  Annu Rev Pharmacol Toxicol       Date:  1982       Impact factor: 13.820

4.  Platelets and atherosclerosis.

Authors:  B B Weksler; R L Nachman
Journal:  Am J Med       Date:  1981-09       Impact factor: 4.965

5.  Platelets intravascular coagulation and fibrinolysis in hyperlipidaemias: relationship to thrombo-embolic complications.

Authors:  A C Carvalho; R S Lees
Journal:  Acta Med Scand Suppl       Date:  1980

6.  Indobufen treatment in type IIA hypercholesterolemic subjects: effects on platelet function and malondialdehyde production.

Authors:  E Tremoli; P Maderna; M Sirtori; S Colli; G Corvi; C R Sirtori
Journal:  Pharmacol Res Commun       Date:  1981-10

7.  Platelet adhesion and aggregation in diabetes mellitus.

Authors:  J A Colwell; R M Nair; P V Halushka; C Rogers; A Whetsell; J Sagel
Journal:  Metabolism       Date:  1979-04       Impact factor: 8.694

8.  The effect of human plasma on platelet function in familial hypercholesterolemia.

Authors:  M Aviram; G J Brook
Journal:  Thromb Res       Date:  1982-04-15       Impact factor: 3.944

9.  Effect of cholesterol on production of thromboxane b2 by platelets in vitro.

Authors:  M J Stuart; J M Gerrard; J G White
Journal:  N Engl J Med       Date:  1980-01-03       Impact factor: 91.245

10.  Platelet function studies in coronary heart disease: VIII. Decreased platelet sensitivity to prostacyclin in patients with myocardial ischaemia.

Authors:  P Mehta; J Mehta
Journal:  Thromb Res       Date:  1980 Apr 1-15       Impact factor: 3.944

View more
  1 in total

Review 1.  Platelet activation in normo- and hyperlipoproteinemias.

Authors:  J Nimpf; H Wurm; G M Kostner; T Kenner
Journal:  Basic Res Cardiol       Date:  1986 Sep-Oct       Impact factor: 17.165

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.